Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Multi-center multinational-controlled study in Israel, Brazil, Spain, and South-Africa.
240 adult patients who suffer from moderate COVID-19 infection. Safety will be assessed
through collection and analysis of adverse events, blood and urine laboratory assessments and
vital signs.
After Screening visit, the study drug will be administrated twice a day morning and evening
(every 12 hours) during (day 1 and day 2) The patients will be randomized in 1:1:1 ratio to
study drug (CimetrA) in two dosages in addition to Standard of Care - Arm 1, 2 or (Placebo)
in addition to Standard of Care- Arm 3.